Blood test could predict who benefits from skin cancer drug
NCT ID NCT07064330
First seen Sep 30, 2025 · Last updated May 23, 2026 · Updated 38 times
Summary
This study aims to find biological markers in the blood and tumor that can predict which patients with a common skin cancer will respond to the immunotherapy drug cemiplimab, and who might experience side effects. Researchers will use advanced cell analysis techniques to study immune cells and molecules from 30 participants. The goal is to personalize treatment and improve outcomes for future patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Complejo Asistencial Universitario de Salamanca
RECRUITINGSalamanca, Salamanca, 37007, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.